1. Home
  2. BTBD vs LGVN Comparison

BTBD vs LGVN Comparison

Compare BTBD & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BT Brands Inc.

BTBD

BT Brands Inc.

N/A

Current Price

$1.80

Market Cap

7.1M

ML Signal

N/A

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$6.60

Market Cap

21.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTBD
LGVN
Founded
1987
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
21.4M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
BTBD
LGVN
Price
$1.80
$6.60
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
37.6K
426.9K
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.76
EPS
N/A
N/A
Revenue
$14,823,472.00
$709,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$10.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$0.48
52 Week High
$2.48
$7.30

Technical Indicators

Market Signals
Indicator
BTBD
LGVN
Relative Strength Index (RSI) 78.08 85.73
Support Level $1.25 $0.61
Resistance Level $1.99 $7.30
Average True Range (ATR) 0.10 0.34
MACD 0.04 0.27
Stochastic Oscillator 90.16 90.01

Price Performance

Historical Comparison
BTBD
LGVN

About BTBD BT Brands Inc.

BT Brands Inc operates and owns a fast-food restaurant called Burger Time. Its offerings include a variety of burgers and other affordable items, including sides and soft drinks. The company owns and operates Keegan's Seafood Grille (Keegan's), a dine-in restaurant located in Florida; Pie In The Sky Coffee and Bakery (PIE), located in Massachusetts; and Schnitzel Haus, a German-themed restaurant located in Florida. The company's revenues are derived from the sale of food and beverages at its restaurants.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: